Abstract
Objectives:To study the effect of ultrashort wave combined with loxoprofen sodium on serum inflammatory factors in patients with acute gouty arthritis.Methods:Records of patients with acute gouty arthritis who were treated in The Fourth Hospital of Changsha from May 2018 to September 2020, were reviewed. Of them, 77 cases were selected and divided into two groups based on the received treatment. The control group (n=39) was treated with loxoprofen sodium, and the treatment group (n=38) was treated with an ultrashort wave combined with loxoprofen sodium, for 10 continuous days. The clinical efficacy of the treatment in two groups was analyzed.Results:After treatment, the quality of life of patients in both groups was improved (P < 0.05), but there was no significant difference in the degree of improvement between the two groups (P > 0.05). After treatment, the VAS score of the treatment group was lower than that of the control group (P < 0.05), the improvement of symptoms and signs of the treatment group was better than that of the control group (P < 0.05). Serum CRP and ESR levels in the treatment group were lower than those in the control group (P < 0.05), and the serum IL-1 β, IL-8, TNF-a and MMP-3 levels of the treatment group were lower than those of the control group (P < 0.05). The total effective rate of the treatment group (94.87%) was higher than that of the control group (87.18%), the difference was statistically significant (P < 0.05). No adverse reactions occurred in all patients during the treatment.Conclusion:An ultrashort wave combined with loxoprofen sodium in the treatment of acute gouty arthritis can reduce the inflammatory reaction, improve the degree of joint pain and swelling, improve the curative effect, and do not increase the adverse reactions. The results may be related to the regulation of IL-1 β, IL-8, TNF-a and MMP-3.
Highlights
Gout is a type of metabolic rheumatism, a heterogeneous disease caused by the disorder of purine metabolism and / or the reduction of uric acid excretion, resulting in long-term high uric acid state and the accumulation of urate.[1]
This study showed that ultrashort wave therapy combined with NSAIDs for treating Acute gouty arthritis (AGA) can significantly improve symptoms and contribute to the recovery of joint function compared to NSAID treatment alone
The study shows that serum inflammatory mediators such as IL-1 β, IL-8, TNF - α and MMP-3 play an important role in the pathological process of AGA and can reflect the clinical efficacy
Summary
Gout is a type of metabolic rheumatism, a heterogeneous disease caused by the disorder of purine metabolism and / or the reduction of uric acid excretion, resulting in long-term high uric acid state and the accumulation of urate.[1] Acute gouty arthritis (AGA) is the most severe form of this disease, with the annual incidence rate of 1.1%.2. In vivo studies show that gout results from monosodium urate (MSU) crystals accumulating excessively in joint capsule, synovial capsule, cartilage and other tissues, resulting in lesions and inflammatory reactions of soft tissues around the joint.[4] There is strong evidence that inflammatory cytokines, such as IL-1 β, IL-8, TNF-a and MMP3 play an important role in the gout pathogenesis.[5] The release of inflammatory cytokines that triggers rapid recruitment of neutrophils to the site of MSU deposition, is the core mechanism of gouty arthritis.[6] Most of the studies of AGA therapy efficiency take symptom score and total effective rate as outcome indicators. While nonsteroidal anti-inflammatory drugs, such as loxoprofen sodium, are considered a first-line gout treatment options that aim at reducing inflammation as quickly as possible,[5] they are associated with risks of gastrointestinal and cardiovascular side effects.[7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
